Post-kala-azar Dermal Leishmaniasis

• FDA approval · 2021-05-25
  FDA Approved: IMPAVIDO — Supplemental Application (Profounda, Inc.)

  The FDA approved a supplemental application for IMPAVIDO (miltefosine) filed by Profounda, Inc.

• FDA approval · 2015-04-10
  FDA Approved: IMPAVIDO — Supplemental Application (Profounda, Inc.)

  FDA approved a supplemental application for IMPAVIDO (miltefosine) filed by Profounda, Inc.

• FDA approval · 2014-03-19
  FDA Approved: IMPAVIDO — Original Application (Profounda, Inc.)

  FDA approved IMPAVIDO (miltefosine) through Profounda, Inc. via Original Application (NDA204684) for visceral leishmaniasis and post-kala-az…